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Development of Primary Invasive Pneumococcal Disease Caused by
Serotype 1 Pneumococci Is Driven by Early Increased Type I
Interferon Response in the Lung
Catherine E. Hughes, Richard M. Harvey, Charles D. Plumptre, James C. Paton
Research Centre for Infectious Diseases, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia
The pneumococcus is the world’s foremost respiratory pathogen, but the mechanisms allowing this pathogen to proceed from
initial asymptomatic colonization to invasive disease are poorly understood. We have examined the early stages of invasive
pneumococcal disease (IPD) by comparing host transcriptional responses to an invasive strain and a noninvasive strain of sero-
type 1 Streptococcus pneumoniae in the mouse lung. While the two strains were present in equal numbers in the lung 6 h after
intranasal challenge, only the invasive strain (strain 1861) had invaded the pleural cavity at that time point; this correlated with
subsequent development of bacteremia in mice challenged with strain 1861 but not the noninvasive strain (strain 1). Progression
beyond the lung was associated with stronger induction of the type I interferon (IFN-I) response in the lung at 6 h. Suppression
of the IFN-I response through administration of neutralizing antibody to IFNAR1 (the receptor for type I interferons) led to sig-
nificantly reduced invasion of the pleural cavity by strain 1861 at 6 h postchallenge. Our data suggest that strong induction of the
IFN-I response is a key factor in early progression of invasive serotype 1 strain 1861 beyond the lung during development of IPD.
Streptococcus pneumoniae (the pneumococcus) is responsiblefor almost 1 million deaths annually in children under the age
of 5 worldwide (1) and is the leading cause of debilitating diseases
such as pneumonia, invasive disease (bacteremia, meningitis),
and otitis media (2). However, despite the enormous burden of
pneumococcal disease, the pathogen is commonly found residing
asymptomatically in the nasopharynx of healthy carriers (3). Ep-
isodes of pneumococcal disease almost always follow at least tran-
sient carriage, usually of a recently acquired strain (3–5). There-
fore, detailed knowledge of the mechanism that underlies the very
early stages of the transition from carriage to disease is fundamen-
tal to understanding pneumococcal pathogenesis.
An intriguing feature of pneumococcal biology is the consid-
erable strain-strain variation in invasive potential that exists, even
between strains of the same serotype (6). By examining a number
of serotype 1 clinical isolates of various levels of invasive capacity,
we previously identified accessory genomic regions (ARs) that
might be responsible for facilitating unusually severe invasive
pneumococcal disease (IPD) in mice and humans (6). That work
showed that while the highly virulent strains, such as strain 1861
(ST 3079), were able to survive in the lungs and rapidly invade the
blood of mice following intranasal (i.n.) challenge, the noninva-
sive strains, such as strain 1 (ST 304), were cleared from the lungs
and not detected in the blood. Interestingly, these strains were
detected in equal numbers in the nasopharynx at both 48 h and 96
h postchallenge, suggesting that the key difference between the
two groups of strains was the ability of the invasive strains to
survive in the lungs and translocate to the blood. While strain-
specific differences between other strains in the capsule and pneu-
molysin (Ply) have been shown to influence the immune response
and alter the course of disease (7), previously studied strains 1 and
1861 produce the same amount of type 1 capsular polysaccharide
and express the same amount of the same variant of Ply (6). A
number of strain-specific bacterial factors with potential roles in
the development of IPD have been identified and are under inves-
tigation. However, the role of the host innate immune response in
the translocation of the pneumococcus from the lungs to the
blood has yet to be elucidated. In addition, the role of the pleural
cavity in the development of IPD is unknown, but it has recently
been suggested to act as the conduit through which pneumococci
pass from the lungs to the blood (8). In this study, we investigated
which elements of the early immune response might influence the
progression of the pneumococcus from the lung to the blood as
well as potential involvement of the pleural cavity. Using PCR
arrays to examine mRNA expression of various key immune genes
in the lung, we have identified a role for the type I interferon
(IFN-I) response in the ability of invasive strain 1861 to progress
beyond the lung to cause invasive disease.
MATERIALS AND METHODS
Bacterial strains and media. S. pneumoniae serotype 1 clinical strains 1
and 1861 used in this study have been described previously (6). Opaque-
phase variants of all strains selected on Todd-Hewitt broth supplemented
with 1% yeast extract (THY)-catalase plates (9) were used in all animal
experiments. Before infection, the bacteria were grown in serum broth
(SB) (nutrient broth [10 g/liter peptone {Oxoid}, 10 g/liter Lab Lemco
powder {Oxoid}, and 5 g/liter NaCl] and 10% [vol/vol] donor horse se-
rum) to an absorbance at 600 nm (A600) of 0.16, which approximates 1
108 CFU/ml.
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Ethics statement. This study was conducted in compliance with the
Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes (7th edition; 2004) and the South Australian Animal Welfare Act
1985. All animal experiments were approved by the Animal Ethics Com-
mittee of the University of Adelaide.
Animal studies. Outbred 5- to 6-week-old female CD1 (Swiss) mice
were used in all animal experiments. For i.n. challenge, mice were anes-
thetized by intraperitoneal (i.p.) injection of sodium pentobarbital (Nem-
butal; Rhone-Merieux) at a dose of 66 g per g of body weight, followed
by i.n. challenge with 50 l of bacterial suspension containing approxi-
mately 1 107 CFU in SB. The challenge dose was confirmed retrospec-
tively by serial dilution and plating on blood agar. At indicated time points
postchallenge, mice were euthanized by CO2 asphyxiation, alternating
between groups throughout to ensure that equivalent time points were
investigated for each comparison. For determining CFU counts, groups of
5 to 12 animals were used, as indicated in the figure legends. Blood was
collected by syringe from the posterior vena cava. The pleural cavity was
subjected to lavage with 1 ml sterile phosphate-buffered saline (PBS) con-
taining 2 mM EDTA introduced through the diaphragm. Pulmonary vas-
culature was perfused by infusion of sterile PBS through the heart. Lungs
for CFU counts were subsequently excised into 2-ml vials containing 1 ml
sterile PBS and 2.8-mm-diameter ceramic beads. Tissues were homoge-
nized using a Precellys 24 tissue homogenizer (Bertin Technologies) at 3
cycles of 30 s at 5,000 rpm. At each time point, a 40-l aliquot of homog-
enized lung was serially diluted in SB and plated on blood agar to deter-
mine the number of CFU present in each lung sample. At 6 h postchal-
lenge, 100-l aliquots of undiluted pleural lavage fluid and blood samples
were plated on blood agar to determine the number of CFU in each sam-
ple. At 24 h postchallenge, 20-l aliquots of blood and pleural lavage
samples were serially diluted and plated on blood agar to determine the
number of CFU in these niches. Data were analyzed in GraphPad Prism
using unpaired t tests or analysis of variance, as described in the figure
legends.
Isolation of RNA. Lungs from resting and challenged mice (n 4 per
group) were excised, following perfusion as described above, and trans-
ferred to 2-ml vials containing 1 ml TRIzol reagent (Life Technologies)
and 2.8-mm-diameter ceramic beads for immediate homogenization as
described above. RNA was isolated from TRIzol-treated samples per the
manufacturer’s instruction. All RNA samples were cleaned using a
PureLink RNA minikit (Life Technologies) per the manufacturer’s in-
struction, including on-column DNase treatment with a PureLink DNase
Set (Life Technologies) to remove any contaminating genomic DNA
(gDNA) before use in quantitative arrays. Removal of gDNA was con-
firmed by PCR amplification of the gene encoding GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) with and without reverse transcrip-
tase.
Quantification of gene expression by PCR array. Gene expression
was analyzed by quantitative reverse transcription-PCR (qRT-PCR) on a
LightCycler 480 II system (Roche), using either the mouse innate and
adaptive immune response RT2 Profiler PCR array or the mouse type I
interferon response RT2 Profiler PCR array with accompanying reagents
(Qiagen), per the manufacturer’s instruction. A detailed explanation of
the control measures included in the array design can be found at the
manufacturer’s website. Briefly, housekeeping genes (Actb, B2m, Gapdh,
Gusb, Hsp90ab1) are included in the array to normalize PCR array data. A
genomic DNA control primer set is included to detect nontranscribed
genomic DNA contamination. Reverse transcription controls (RTC) are
included to determine cDNA synthesis efficiency, and positive PCR con-
trols (PPC) are included to test the efficiency of the PCR itself. The latter
two controls (RTC and PPC) also test for interwell and intraplate effi-
ciency. Data were analyzed using PCR Array Data Analysis Software pro-
vided by the manufacturer.
Suppression of IFN-I response. For IFNAR1 neutralization, mice
were i.p. administered 300 g of anti-IFNAR1 antibody (clone MAR1-
5A3, low-endotoxin functional grade; Leinco Technologies) (10) or an
isotype control at 48 h and 24 h prior to bacterial challenge. At 0 h, animals
were i.n. administered 100 g of antibody or isotype, concurrent with
bacterial challenge. Tissues were retrieved and processed for bacterial
counts as described above. Suppression of the IFN-I response due to anti-
IFNAR1 treatment was confirmed by comparing the levels of expression
of the IFN-stimulated Cxcl10 and Ifng genes in lungs from resting, un-
treated mice and 1861-infected mice treated with isotype control or anti-
IFNAR1, each at 6 h postchallenge (n  4 per group). qRT-PCR was
performed using a Superscript III One-Step RT-PCR kit (Invitrogen) and
primers RHCxcl10F (5=-AGT GCT GCC GTC ATT TTC TG-3=),
RHCxcl10R (5=-ATT CTC ACT GGC CCG TCA T-3=), RHIFNgF (5=-
CGG CAC AGT CAT TGA AAG CCT A-3=), and RHIFNgR (5=-GTT GCT
GAT GGC CTG ATT GTC-3=) on a LightCycler 480 II system (Roche).
Cxcl10 and Ifng expression was normalized to Gapdh expression using
primers GAPDHF (5=-TCC TTG GAG GCC ATG TGG GCC AT-3=) and
GAPDHR (5=-TGA TGA CAT CAA GAA GGT GGT GAA G-3=). Data are
presented for each gene as fold differences relative to resting conditions.
RESULTS
Pleural cavity invasion as an early marker of invasive capacity.
The pathogenesis of noninvasive (strain 1) and highly invasive
(strain 1861) serotype 1 strains was characterized using an i.n.
mouse challenge model. Following analysis of bacterial burdens in
various niches at early time points (4 to 12 h postchallenge; data
not shown), a time point of 6 h postchallenge (6 h) was chosen to
investigate the early stages of disease, as this was the earliest time
point at which bacteria could be reliably detected in the pleural
cavity. Samples from 24 h postchallenge (24 h) provided confir-
mation of the divergent patterns of invasion reported previously
for these strains (6). At 6 h, the two strains were detected in the
lungs in equal numbers. However, strain 1 was significantly re-
duced in numbers by 24 h (Fig. 1A), consistent with its previously
observed clearance from the lungs by 48 h (6). In contrast, strain
1861 persisted in the lung at 24 h (Fig. 1A). Investigation of the
bacterial burden in the pleural cavity at these time points revealed
a striking difference between the two strains. While strain 1 re-
mained below the limit of detection throughout the experiment,
strain 1861 was detected at low levels at 6 h in almost all mice and
was present by 24 h in very high numbers (approximately 108
CFU/pleural cavity in all samples) (Fig. 1B). This pattern corre-
lated with that seen in the blood, where strain 1 was undetectable
in all samples whereas strain 1861 was detected at very low levels in
some 6-h samples and was present in significant numbers in all
blood samples at 24 h (Fig. 1C). These data suggest that invasion of
the blood leading to bacteremia is preceded by invasion of the
pleural cavity, as has been previously proposed (8), and that inva-
sion of the normally sterile pleural cavity may be used as an early
marker of invasion. The data also show that whereas pleural cavity
invasion by strain 1861 had commenced at 6 h, this was not due to
a difference in bacterial numbers in the lung from those deter-
mined for strain 1 but was likely due to a difference in the inter-
actions between the host and the two bacterial strains within the
lung. Therefore, the host immune response in the lung at this time
point was investigated to identify factors that might explain the
different pathogenic profiles of these strains.
Proinflammatory response to challenge with serotype 1
strains in the lung. The immune response in the lungs was char-
acterized broadly at the level of transcription, using real-time RT-
PCR to perform quantitative expression analysis of 84 key im-
mune response genes. Total RNA was isolated from lung samples
collected 6 h after challenge with strain 1 or strain 1861 as well as
Hughes et al.
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from lung samples from unchallenged “resting” control mice.
Compared with resting lung samples, 21 of 84 genes were found to
be differentially regulated (fold change 2, P 0.05, n 4) in a
strain-independent manner (Table 1; see also Table S1 in the sup-
plemental material). Of these, 20 showed increased expression
compared to resting lung samples following challenge with either
strain. Upregulated genes included those encoding proinflamma-
tory cytokines such as interleukin-1 beta (IL-1), IL-6, IL-23a,
FIG 1 Pathogenesis of serotype 1 isolates in mice following intranasal challenge. Groups of 9 to 10 mice were challenged i.n. with 107 CFU of either strain 1 or strain 1861.
The total number of CFU recovered from lungs (A), the pleural cavity (B), or blood (C) was determined at 6 h or 24 h postchallenge, as indicated. The horizontal broken
lines in each strain group indicate the geometric mean number of CFU that were recovered. Statistical differences were analyzed by a two-tailed unpaired t test using
log-transformed values (****,P 0.0001). The single horizontal spotted line indicates the limit of detection (LD). At 6 h, this equates to 102 CFU/lung, 10 CFU/pleural
cavity, and 10 CFU/ml blood. At 24 h, it equates to 102 CFU/lung, 2 102 CFU/pleural cavity, and 2 102 CFU/ml blood.
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and tumor necrosis factor alpha (TNF-) as well as the inflam-
masome component NLRP3 and a range of other immune modula-
tory factors such as the chemokine receptor CCR5, CD14, costimu-
latory molecules CD80 and CD86, granulocyte-macrophage colony-
stimulating factor (GM-CSF; Csf2), the integrin CD11b (Itgam), and
the associated adhesion molecule ICAM1. A number of pattern rec-
ognition receptors, both intra- and extracellular, including Toll-like
receptor 4 (TLR4), TLR5, TLR8, and Nod2, were also differentially
regulated. Of all the genes differentially regulated in a strain-indepen-
dent manner, only Tlr5 was downregulated in comparison to resting
controls. These data show that the two strains are recognized by the
murine immune system and induce broadly similar, generally proin-
flammatory responses. Data for the complete array of 84 genes ana-
lyzed can be found in Table S1.
Differential regulation of immune response genes by inva-
sive and noninvasive strains. Analysis of genes that showed
strain-dependent differential expression revealed a significant in-
crease in expression of 8 genes in the lungs by 6 h postchallenge
with strain 1861 compared to strain 1 (Table 2). Of these genes, 7
are associated with an IFN-I response, while expression of Ifng,
encoding type II gamma interferon (IFN-), was also increased in
a strain-dependent manner. Of the 7 IFN-I-related genes identi-
fied, expression levels of 3 were found to be significantly elevated,
with a greater than 2-fold change in expression, in lungs from
mice challenged with either strain compared to resting mice, as
was the expression level of Ifng (Table 3). Expression levels of the
remaining 4 genes were significantly upregulated compared to the
levels seen with resting samples only after challenge with strain
1861. These data suggest that, although the two strains induce
broadly similar responses, the IFN-I response induced by strain
1861 is stronger than that induced by strain 1.
The IFN-I response is exacerbated in lungs from animals
challenged with strain 1861. To verify the response indicated by
the data reported above, a more comprehensive set of genes asso-
ciated with the IFN-I response was analyzed by a real-time RT-
PCR array. This confirmed that both strains induced an IFN-I
response (see Table S2 in the supplemental material), with 61 of 84
genes differentially regulated by at least one of the two bacterial
strains compared to resting conditions, including some identified
in the previous array. Of these, 40 genes were induced by both
strains compared to resting controls. Strain-independent in-
creases in expression were observed in 16 of these genes as listed in
Table 4. The remaining 24 genes were found to be more strongly
induced in lungs from animals challenged with strain 1861 than in
lungs from those challenged with strain 1 (Table 5). An additional
5 genes were found to be specifically altered in expression by strain
1861 compared to strain 1 (Table 6). Of these 5 genes, 4 were
TABLE 1 Strain-independent differential regulation of immune
response genes in lungs at 6 h postchallengea
Gene symbol
Strain 1 vs resting Strain 1861 vs resting
Fold change Significance Fold change Significance
Casp1 2.55 * 4.42 **
Ccr5 3.44 * 3.18 *
Cd14 36.69 * 28.55 ***
Cd80 13.00 * 5.97 ****
Cd86 2.51 * 4.49 **
Csf2 14.25 *** 9.42 ****
Icam1 4.37 ** 4.05 **
Il1a 12.51 *** 20.08 ****
Il1b 56.20 ** 63.47 ****
Il1r 3.62 ** 3.31 ***
Il23a 36.57 ** 51.20 **
Il6 146.02 *** 161.79 *
Itgam 6.55 ** 12.58 **
Jak2 2.86 * 3.85 *
Nlrp3 38.19 ** 54.21 **
Nod2 9.66 * 19.07 *
Slc11a1 3.47 * 2.62 *
Tlr4 2.70 * 5.32 *
Tlr8 2.57 ** 2.40 *
Tnf 71.26 * 55.16 *
Tlr5 	2.26 ** 	3.69 ***
a Animals (n 4 per group) were challenged with 107 CFU of strain 1 or strain 1861 or
left unchallenged (“resting”). Lungs were harvested for RNA isolation at 6 h
postchallenge, and immune response gene expression was analyzed using mouse innate
and adaptive immune response RT2 Profiler PCR arrays (cutoff, fold change 2). Data
represent changes in gene expression in lungs from challenged animals relative to
resting controls. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
TABLE 2 Strain-dependent induction of immune response genes in
lungs at 6 h postchallenge with strain 1861 versus strain 1 suggests
involvement of the IFN-I responsea
Gene symbol
Strain 1861 vs strain 1
Fold change Significance
Crp 6.91 *
Cxcl10 5.11 *
Ifna2 3.69 *
Ifng 6.22 **
Il10 2.22 *
Irf7 2.73 *
Mx1 3.39 *
Stat1 3.50 *
a Animals (n 4 per group) were challenged with 107 CFU of strain 1 or strain 1861 or
left unchallenged (“resting”). Lungs were harvested for RNA isolation at 6 h
postchallenge, and immune response gene expression was analyzed using mouse innate
and adaptive immune response RT2 Profiler PCR arrays (cutoff used, fold change 2).
Data represent changes in gene expression in lungs from animals challenged with strain
1861 relative to lungs from animals challenged with strain 1. *, P 0.05; **, P 0.01;
***, P 0.001; ns, not significant (P 0.05).
TABLE 3 Strain-dependent induction of immune response genes in
lungs at 6 h postchallenge with strain 1861 and strain 1 versus resting
conditions suggests involvement of the IFN-I responsea
Gene symbol
Strain 1 vs resting Strain 1861 vs resting
Fold change Significance Fold change Significance
Crp 1.19 ns 8.20 *
Cxcl10 662.83 ** 3,386.31 **
Ifna2 2.64 ns 9.77 *
Ifng 55.52 ** 345.61 **
Il10 5.50 * 12.21 ***
Irf7 7.29 ns 19.88 **
Mx1 16.97 * 57.60 ***
Stat1 1.99 * 6.94 *
a Animals (n 4 per group) were challenged with 107 CFU of strain 1 or strain 1861 or
left unchallenged (“resting”). Lungs were harvested for RNA isolation at 6 h
postchallenge, and immune response gene expression was analyzed using mouse innate
and adaptive immune response RT2 Profiler PCR arrays (cutoff used, fold change 2).
Data represent changes in gene expression in lungs from challenged animals relative to
resting controls. *, P 0.05; **, P 0.01; ***, P 0.001; ns, not significant (P 0.05).
Italicized values indicate fold changes that do not meet both the cutoff and P value
requirements for significance.
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found to be significantly increased in expression following chal-
lenge with the invasive strain. The apparent downregulation of the
fifth gene, Traf3, is likely due to a slight (2-fold) decrease in
expression seen with strain 1861 compared to resting conditions
coupled with a slight but not statistically significant increase in
expression of the same gene following challenge with strain 1 (see
Table S2 in the supplemental material). Together, these data fur-
ther suggest that the ability of strain 1861 to invade involves an
amplification of the IFN-I response. Data for the complete array of
IFN-I response genes analyzed are shown in Table S2.
Suppression of the IFN-I response inhibits progression of
strain 1861 to the pleural cavity. To confirm the importance of
TABLE 4 Strain-independent induction of genes involved in the IFN-I
response in lungs at 6 h postchallengea
Gene symbol
Strain 1 vs resting Strain 1861 vs resting
Fold change Significance Fold change Significance
Adar 2.09 ** 3.6 *
Ccl5 2.75 * 2.88 *
Cd69 4.69 ** 16.85 *
Cd80 21.59 * 24.29 ***
Cd86 4.07 * 5.98 **
Ifitm3 2.65 *** 4.68 ****
Ifna2 5.99 * 17.26 *
Ifnb1 66 * 106.12 *
Il6 229.84 * 256.8 ****
Irf9 2.91 ** 5.28 ***
Jak2 3.07 ** 5.21 ****
Oas2 4.16 **** 7.9 **
Stat3 2.8 ** 4.01 ****
Tap1 5.37 *** 8.48 ***
Timp1 25.32 ** 63.21 *
Tlr8 2.01 * 2.29 *
a Animals (n 4 per group) were challenged with 107 CFU of strain 1 or strain 1861 or
left unchallenged (“resting”). Lungs were harvested for RNA isolation at 6 h
postchallenge, and immune response gene expression was analyzed using mouse type I
interferon response RT2 Profiler PCR arrays (cutoff used, fold change 2). Data
represent changes in gene expression in lungs from challenged animals relative to
resting controls. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
TABLE 5 Strain 1861 induces stronger upregulation of genes involved in the IFN-I response than strain 1 compared to resting conditionsa
Gene symbol
Strain 1 vs restingb Strain 1861 vs restingb Strain 1861 vs strain 1c
Fold change Significance Fold change Significance Fold change Significance
Ccl2 102.86 **** 421.53 ** 4.1 **
Ccl4 205.36 ** 817.17 **** 3.98 ***
Cxcl10 1,490.93 * 5,770.58 ** 3.87 *
Ddx58 3.1 *** 6.21 *** 2 **
Eif2ak2 3.94 *** 16.62 **** 4.22 ***
Gbp1 8.95 **** 29.33 **** 3.28 ***
Ifi204 7.78 * 18.82 *** 2.42 *
Ifih1 4.69 *** 20.39 ** 4.35 *
Ifit1 24.37 *** 77.82 ** 3.19 *
Ifit2 21.25 *** 105.02 *** 4.94 ***
Ifit3 3.09 *** 9.22 ** 2.98 **
Ifitm1 4.21 *** 8.56 ** 2.03 *
Il10 7.23 *** 14.85 *** 2.05 *
Il15 2.7 ** 9.95 **** 3.69 ***
Irf1 5.33 **** 11.59 *** 2.17 **
Irf7 7.32 ** 19.83 *** 2.71 **
Isg15 26.3 ** 110.24 ** 4.19 **
Isg20 3.21 **** 7.31 *** 2.27 **
Mx1 24.08 * 67.74 **** 2.81 *
Mx2 14.12 *** 34.05 ** 2.41 *
Oas1a 5.59 *** 18.76 **** 3.36 ***
Psme2 2.26 * 5.88 ** 2.6 *
Stat1 3.1 * 10.02 *** 3.23 **
Stat2 3.38 * 8.98 **** 2.66 **
a Animals (n 4 per group) were challenged with 107 CFU of strain 1 or strain 1861 or left unchallenged (“resting”). Lungs were harvested for RNA isolation at 6 h postchallenge,
and immune response gene expression was analyzed using mouse type I interferon response RT2 Profiler PCR arrays (cutoff used, fold change 2). *, P 0.05; **, P 0.01; ***,
P 0.001; ****, P 0.0001.
b Data represent changes in gene expression in lungs from challenged animals relative to resting controls.
c Data represent changes in gene expression in lungs from animals challenged with strain 1861 relative to lungs from animals challenged with strain 1.
TABLE 6 Strain 1861 specifically differentially regulates a subset of
genes involved in the IFN-I responsea
Gene symbol
Strain 1861 vs strain 1
Fold change Significance
Bst2 7.89 *
Crp 4.73 *
H2-k1 2.55 **
Nos2 2.76 *
Traf3 	2.13 *
a Animals (n 4 per group) were challenged with 107 CFU of strain 1 or strain 1861 or
left unchallenged (“resting”). Lungs were harvested for RNA isolation at 6 h
postchallenge, and immune response gene expression was analyzed using mouse type I
interferon response RT2 Profiler PCR arrays (cutoff used, fold change 2). Data
represent changes in gene expression in lungs from animals challenged with strain 1861
relative to lungs from animals challenged with strain 1. *, P 0.05; **, P 0.01.
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the IFN-I response in the progression to invasive disease, groups
of mice were treated with either anti-IFNAR1 antibody, which
blocks the IFN-I response (10, 11), or an isotype control and were
challenged with either strain 1 or strain 1861. Activity of the anti-
body was confirmed by determining relative expression levels of
the IFN-I-stimulated Cxcl10 and Ifng genes for both resting mice
and mice treated with either isotype control or anti-IFNAR1 an-
tibody and challenged with strain 1861, with samples taken at 6 h
postchallenge (see Fig. S1 in the supplemental material). Numbers
of pneumococci in the lungs, pleural cavity, and blood were quan-
tified at both 6 h and 24 h postchallenge. Numbers in the lungs
were unaffected by antibody treatment for either strain at both
time points (Fig. 2A), suggesting that the IFN-I response is not
responsible for the difference between strains 1 and 1861 in the
survival rates in the lungs. However, at 6 h postchallenge with
strain 1861, we observed a significant decrease in bacterial inva-
sion of the pleural cavity following treatment with anti-IFNAR1
antibody compared to treatment with the isotype control (Fig.
2B). Not only was the mean number of CFU per pleural cavity
lower in the antibody-treated group than in the isotype-treated
group (one-tailed t test, Welch corrected, P 0.035), there were
also significantly fewer animals in the antibody-treated group with
detectable pneumococci in the pleural cavity than in the isotype-
treated group, as determined by Fisher’s exact (one-tailed) test (P
 0.0296). By 24 h, this difference was no longer apparent (Fig.
2B). At 6 h, only a small number of animals challenged with strain
1861 had detectable CFU in the blood, with or without antibody
treatment, while all animals developed bacteremia by 24 h follow-
ing challenge with strain 1861 (Fig. 2C). Strain 1 was not detect-
able in the pleural cavity or blood at any time point with either
treatment. These data suggest that suppression of the IFN-I re-
sponse hinders progression of strain 1861 from the lungs to the
pleural cavity but does not impede proliferation of the strain in the
pleural cavity.
DISCUSSION
The mechanisms that underlie the progression of S. pneumoniae
from asymptomatic carriage to invasive disease are fundamental
to pneumococcal pathogenesis. While many studies investigating
the development of IPD have focused on the properties of the
pathogen, it is clear that the host immune response is a critical
element in the invasive process. In this study, we demonstrated
that differences in the early immune response to two closely re-
lated serotype 1 strains play a key role in determining their ability
to progress beyond the lung and cause IPD. Strong induction of an
IFN-I response by strain 1861 leads to rapid invasion of the pleural
cavity with subsequent development of severe bacteremia that is
absent from mice challenged with noninvasive strain 1. Suppres-
sion of this response in animals challenged with strain 1861 delays
the initial invasion of the pleural cavity.
The focus in this study on the earliest stages of IPD enabled the
elucidation of the mechanisms involved in the transition from the
lung to IPD rather than of the events occurring after bacteremia
has been established. We have demonstrated that for invasive
strain 1861, invasion of the pleural cavity as early as 6 h postchal-
lenge consistently precedes detection of bacteria in the blood-
stream. This supports the notion that the pleural cavity may act as
a conduit for bacteria to travel from the lung to the blood (8) and
highlights this niche as an important site for investigation of host-
pathogen interaction in pneumococcal disease.
As the two strains were detected in equal numbers in the lungs
at the 6-h time point, it is clear that the difference in invasive
capacity is not simply a dose-dependent case of an overwhelming
bacterial burden in or a failure to clear bacteria from this niche.
Instead, when we look more closely at the immune response in the
lung at this early stage, a more complex interplay between host
and pathogen becomes apparent. Both strains induce a broadly
proinflammatory response, causing upregulation of genes encod-
ing various proinflammatory cytokines, pattern recognition re-
ceptors (PRRs), costimulatory molecules, and other immune
modulators. However, some clear indications of divergence were
observed. Although both strains induced an IFN-I response, a
subset of genes indicative of an IFN-I response was more strongly
upregulated by invasive strain 1861 than by noninvasive strain 1
compared to resting levels. Strain 1861 also uniquely upregulated
several other IFN-I-related genes whose expression remained un-
changed in the presence of strain 1. This, coupled with the dem-
onstration that inhibition of the IFN-I response using anti-
IFNAR1 led to decreased invasion into the pleural cavity at 6 h for
strain 1861, indicates that the relative scale of the IFN-I response,
which is independent of the bacterial numbers present in the
lungs, is a critical factor in progression to IPD from the lungs for
these strains. In previous work, 8 accessory genomic regions
(ARs)
1 kb in size were found to be present in the genome of the
highly virulent strains, including strain 1861, but absent from
the less virulent strains, which included strain 1 (6). In particular,
the version of the variable region of pneumococcal pathogenicity
island 1 present in strain 1861 (PPI-1v1861) was responsible for a
greater competitive advantage in the lungs and blood of infected
mice than the equivalent region present in strain 1 (PPI-1v1) when
both were expressed in the D39 background. Therefore, it is
tempting to speculate that PPI-1v1861 might be responsible for a
stronger IFN-I response in the lungs of mice than PPI-1v1. How-
ever, given that there is little known about the proteins encoded in
either PPI-1v or the remaining 7 ARs, it is possible that any one
region or combination of these regions might be responsible for
the differences in the initial immune response to strains 1 and
1861.
IFN-Is are widely known to be induced in response to viruses,
as well as during some intracellular bacterial infections (12). In
recent years, it has become clear that IFN-Is are also involved in
the response to the pneumococcus, as shown for a variety of sero-
types. Previous studies have suggested a specific involvement of
the IFN-I response in nasopharyngeal colonization for both a se-
rotype 2 strain (13, 14) and a serotype 23F strain (15). For the
latter strain, increasing the IFN-I response either artificially or
through coinfection with influenza virus led to increased levels of
pneumococcal colonization of the nasopharynx. This was attrib-
uted to an IFN-I-dependent inhibition of macrophage recruit-
ment to the site of colonization (15). Recent work has also high-
lighted the importance of the IFN-I response in susceptibility to
development of IPD (16, 17). Using serotype 3 strain ATCC 6303,
Shahangian and colleagues reported that prior infection with in-
fluenza virus rendered mice more sensitive to secondary pneumo-
coccal infection, an effect abrogated either by administration of
neutralizing antibody against IFNAR1 or through use of an
IFNAR1-null mouse (16). The IFN-I-dependent effect was linked
to impaired CXC chemokine production, required for neutrophil
recruitment. Similarly, artificial induction of an IFN-I response
led to decreased survival rates and increased bacterial burden in
Hughes et al.
3924 iai.asm.org Infection and Immunity
 o
n
 Septem
ber 27, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://iai.asm
.org/
D
ow
nloaded from
 
FIG 2 Suppression of the IFN-I response delays invasion of the pleural cavity by strain 1861. Mice were treated with anti-IFNAR1 neutralizing antibody (Ab;
open circles) or an isotype control (Iso; closed circles) and challenged i.n. with 107 CFU of either strain 1 or strain 1861. The total number of CFU recovered from
lungs (A), the pleural cavity (B), or blood (C) was determined at 6 h or 24 h postchallenge, as indicated. The horizontal broken lines in each strain group indicate
the geometric mean number of CFU that were recovered. In panel B, statistical differences were analyzed by a one-tailed unpaired t test using log-transformed
values (*, P 0.05). The single horizontal spotted line indicates the limit of detection (LD). At 6 h, this equates to 102 CFU/lung, 10 CFU/pleural cavity, and 10
CFU/ml blood. At 24 h, it equates to 102 CFU/lung, 2 102 CFU/pleural cavity, and 2 102 CFU/ml blood. Group sizes were as follows: n 5 to 6 for strain 1
challenge groups; n 7 to 8 for blood and lung samples from 6-h strain 1861 challenge groups; n 7 to 8 for lung samples from 24-h 1861 challenge groups; n
11 to 12 for all other groups.
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both the lungs and the blood of mice with strain ATCC 6303 that
persisted for up to 4 days after challenge (17). In contrast, others
have indicated that the induction of an IFN-I response to the
pneumococcus can be beneficial to the host, at least in the case of
challenge with derivatives of commonly used serotype 2 strain
D39. Parker and colleagues found that, in contrast to studies using
other serotypes, induction of IFN-Is led to improved clearance of
D39 from the nasopharynx (14), while a more recent study dem-
onstrated that variants of the serotype 2 strain were less invasive in
the presence of a robust IFN-I response (18), a finding linked to
reduced lung permeability following induction of IFN-I and a
corresponding reduction in platelet-activating factor (PAF) re-
ceptor expression.
These studies indicate that the serotype and strain of S. pneu-
moniae used in each study are critical to the outcome. Our data
show that, for the clinically relevant serotype 1 strains tested in this
study, the strength of the IFN-I response induced during primary
infection is a key factor in determining the ability to invade. These
data are in parallel with those from a study published earlier this
year which indicated that the strength of induction of a IFN-I
response is a determining factor in the pathogenicity of strains of
Staphylococcus aureus, another important human pathogen, in a
pneumonia model (19). As described for the strains investigated
in our work, the strength of the response to S. aureus was found to
correlate with increased virulence in a murine model. The report
showed that, while both S. aureus strains used induced an IFN-I
response in vitro, the response induced by the more virulent strain
was much stronger, and the ability of this strain to cause invasive
disease was significantly reduced in an IFNAR-null mouse. In
comparisons of lungs from animals infected i.n., those lacking the
IFN-I response had less-severe pulmonary pathology, with IFN-I
signaling linked to increased tissue damage in the infected lung
(19). This contrasts with the results of a study by LeMessurier and
colleagues, which attributed decreased lung permeability to an
increase in IFN-I levels. These studies, as well as the work pre-
sented here, indicate that the effect of IFN-I induction in response
to infection is dependent on the strength of the response induced,
which varies in a strain-dependent manner.
The ability to progress beyond the lung and invade normally
sterile compartments of the host is a critical factor in the patho-
genicity of the pneumococcus. By examining the very early stages
of pneumococcal disease progression, we have shown that pleural
cavity invasion by serotype 1 strain 1861 precedes detectable bac-
teremia, bolstering confidence in the suggestion that the pleural
cavity can act as a gateway to dissemination throughout the host.
Crucially, we have also demonstrated for the first time that S.
pneumoniae can induce a strong IFN-I response early in primary
pneumococcal infection that promotes progression of the pneu-
mococcus from the lung to the pleural cavity, with subsequent
development of IPD.
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